# US 2010/0167285 A1 · Methods and agents for evaluating inflammatory bowel disease, and targets for treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167285 A1
- Document ID: US20100167285A1
- Status: Published application
- Kind: A1
- Application number: 12/450,478
- Filed: 2008-03-26
- Published: 2010-07-01
- Earliest claimed: 2007-03-26
- Inventors: Stefan Schreiber; Philip Rosenstiel; Andreas Ruether; Andre Franke; John Raelson; Randall D. Little; Tim Keith; Helene Fournier
- Web page: https://patentgrep.com/patent/US20100167285A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides methods for evaluating irritable bowel disease (IBD), including Crohn Disease and Ulcerative Colitis, methods for determining a patient's susceptibility to developing an IBD, and methods for determining a patient's IBD genotype. The invention includes methods, polynucleotides, polypeptides, and antibodies relating to disclosed variants of, and polymorphisms in, the nel-like 1 precursor (NELL1), as well as the 5p13.1 locus, and other genes disclosed herein to be associated with IBD. Thus, the invention provides diagnostic and/or therapeutic targets for IBD, as well as diagnostic and therapeutic agents for IBD.

## Claims

### Claim 1

A method for determining inflammatory bowel disease (IBD) genotype in a patient suspected of having an IBD, or for determining a patient's susceptibility to develop an IBD, said method comprising: determining the presence or absence of one, or a combination of, single nucleotide polymorphisms (SNPs) in a biological sample from said patient, said SNP(s) being listed in any one of Tables 1-5.

### Claim 2 (depends on 1)

The method of claim 1, wherein the SNP(s) are listed in any one of Tables 2-5.

### Claim 3 (depends on 1)

The method of claim 1, wherein the SNP(s) is selected from the group consisting of: rs2076756, rs1992662, rs1992660, rs1793004, rs10521209, rs2631372 and combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the SNP(s) is associated with a mutation in the gene encoding the nel-like 1 precursor (NELL1) in said biological sample from said patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the SNP is listed in Tables 1, 2, and/or 4.

### Claim 6 (depends on 5)

The method of claim 5, wherein the of SNP(s) is rs17930044.

### Claim 7 (depends on 1)

The method of claim 1, wherein the SNP(s) is associated with a mutation in the 5p13.1 locus in said biological sample from said patient.

### Claim 8 (depends on 7)

The method of claim 7, wherein the SNP(s) is listed in Tables 1, 3, and/or 5.

### Claim 9 (depends on 8)

The method of claim 8, wherein the SNP(s) is selected from the group consisting of rs1992662 and rs19926604.

### Claim at position 10

-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein said IBD is Crohn's disease or ulcerative colitis.

### Claim 14

(canceled)

### Claim 15 (depends on 4)

The method of claim 4, further comprising, determining the level of expression and/or activity of NELL1 in said biological sample from said patient.

### Claim 16 (depends on 1)

The method of claim 1, further comprising, determining the presence or absence of one or more of the following: a mutation in the CARD15 gene, a mutation in the DLG5 gene, a mutation in the TNFSF15 gene, a mutation in the IL23R gene, and/or a T300A mutation in the ATG16L1 gene.

### Claim 17 (depends on 4)

The method of claim 4, further comprising determining the presence or absence of a mutation in the 5p13.1 locus.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mutation is associated with the presence or absence of SNP rs1992662 and/or rs1992660.

### Claim at position 17

-21. (canceled)

### Claim 22

A kit for determining inflammatory bowel disease (IBD) genotype in a patient suspected of having an IBD, or for determining a patient's susceptibility to develop an IBD, said kit comprising a set of nucleic acid probes and/or primers specific designed to detect two or more SNP(s) listed in any one of Tables 1-5, wherein the set of probes and/or primers consists essentially of probes and/or primers related to evaluating said IBD genotype and probes and/or primers related to assay controls.

### Claim 23 (depends on 22)

The kit of claim 22, wherein the kit comprises nucleic acid probes specific for two or more SNP(s) listed in any one of Tables 2-5.

### Claim 24 (depends on 22)

The kit of claim 22, wherein the kit comprises nucleic acid probes specific for two or more SNP(s) selected from the group consisting of: rs2076756, rs1992662, rs1992660, rs1793004, rs10521209, and rs2631372.

### Claim 25 (depends on 22)

The kit of claim 22, wherein the kit comprises nucleic acid probes specific for each of rs2076756, rs1992662, rs1992660, rs1793004, rs10521209, and rs2631372.

### Claim 26

A NELL1 polypeptide comprising at least one amino acid substitution that is associated with IBD.

### Claim 27 (depends on 26)

The polypeptide of claim 26, wherein the polypeptide comprises one or more amino acid substitutions selected from Q82R, R136S, A153T or R354W.

### Claim 28 (depends on 26)

A polynucleotide encoding the polypeptide of claim 26.

### Claim 29 (depends on 28)

A host cell harboring the polynucleotide of claim 28.

### Claim 30 (depends on 26)

An antibody specific for or raised against the polypeptide of claim 26.

### Claim at position 27

-32. (canceled)

### Claim 33

A method for identifying an agent for treating IBD, comprising contacting a NELL1 polypeptide with a test agent, and determining a change in the level of NELL1 activity as a result of the test agent.

### Claim 34 (depends on 4)

The method of claim 4, wherein said patient is suffering from sarcoidosis, is suspected of having sarcoidosis, or is suffering from symptoms of sarcoidosis.

### Claim 35 (depends on 34)

The method of claim 34, wherein the SNP is rs951199.
